This page is available in multiple languages
Select Language

Medica S.p.A. lists on Euronext Growth Milan


  • Twenty-sixth listing of 2021 on Euronext Growth Milan
  • Medica S.p.A. brings the total number of companies listed on Euronext Growth Milan to 157
  • Total placement volume of the offering equal to €22.9 million


Milan – 3 November 2021 – Borsa Italiana, part of the Euronext Group, today congratulates Medica S.p.A. on its listing on Euronext Growth Milan.

Medica S.p.A. operates in the biomedical sector. The company’s core business is the development of innovative products for blood purification.

Medica S.p.A. represents the twenty-sixth listing since the beginning of the year on Borsa Italiana’s market dedicated to small and medium sized companies and it brings the total number of firms currently listed on Euronext Growth Milan to 157.

In the placement phase, Medica S.p.A. raised €20.2 million, excluding the potential exercise of an over-allotment option. In the case of full exercise of the over-allotment option, the total amount raised will be €22.9 million. The free float at the time of admission was 17.7% and the market capitalisation at IPO was €114.0 million.

Luciano Fecondini, Chairman and CEO of Medica S.p.A., said:

"We are certainly proud of the results of the IPO process. Thanks to the listing, we will have the resources to carry on with innovative projects of significant size, and to accelerate our growth through focused and synergistic acquisitions. We also welcome the presence of international investors among new shareholders, in line with our international footprint. Listing on Euronext Growth Milan is a first step towards the achievement of an ambitious, long-term vision, being aware of our growth potential both in the medical and water purification fields."

Medica Bell ringing

Luciano Fecondini, Chairman and CEO of Medica S.p.A., rang the bell during the market open ceremony this morning to celebrate the Initial Public Offering of the company.

About Medica Group Medica Group has been in operation since 1985 in the Mirandola Biomedical District of (Italy). Development of innovative products for blood purification has always been company’s core business. Thanks to the activity of two extremely dynamic R&D groups (medical equipment, membranes and disposables), the Group competes successfully in several markets, namely:

  • Medical (dialysis, CRRT, ECCO2, Apheresis, DFPP, CHF, HIPEC, pre-transplant organ perfusion, bioregenerative medicine, gastroenterology, urodynamics, oxygen humidification)

  • Microbiological purification of water

  • Industrial automation for the biomedical sector

R&D focus has been integrated over the years with highly automated production systems in five different facilities, four in Italy and one in Tunisia, and two commercial entities (in the US and in China). The key success factors of the Group are:

  • Extrusion of hollow fibre membranes for hemofiltration, plasmapheresis, cascade filtration, oxygen humidification, ultrafiltration and microfiltration of water

  • Vertical integration, proven by the ability to manage not only the design and development of medical disposables and equipment, but also the development of the automation technologies required for their production.

  • International recognition with significant share of export (69% of revenues in 2020), with sales in over 60 countries.

Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With more than 1,900 listed issuers and around €6.5 trillion in market capitalisation as of end June 2023, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter ( and LinkedIn (

This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at

© 2023, Euronext N.V. - All rights reserved.